Document:

<PAGE>

                                                                   EXHIBIT 10.30

                       (TRUBION PHARMACEUTICALS(TM) LOGO)

January 20, 2006

Michelle Burris
20235 SE 19th Street
Sammamish, Washington

Dear Michelle,

     I am pleased to offer you a position with Trubion Pharmaceuticals, Inc.
(the "Company"), as the Senior VP, Chief Financial Officer, reporting to me,
commencing on January 31, 2006. If you decide to join us, you will receive an
annual salary of $300,000, which will be paid semi-monthly in accordance with
the Company's normal payroll procedures. As an employee, you will also be
eligible to receive certain employee benefits including health & dental
insurance, and participation in the Company's 401(k) plan. You should note that
the Company might modify job titles, salaries and benefits from time to time, as
it deems necessary.

     In addition, if you decide to join the Company, it will be recommended at
the first meeting of the Company's Board of Directors following your start date
that the Company grant you an option to purchase 500,000 shares of the Company's
Common Stock at a price per share equal to the fair market value per share of
the Common Stock on the date of grant, as determined by the Company's Board of
Directors. The shares subject to this grant will be subject to normal Company
vesting requirements, with 25% of the shares subject to this grant vesting on
the one-year anniversary of your start date, and the remainder vesting
thereafter in equal monthly installments, such that the shares subject to this
grant will be fully vested on the four-year anniversary of your start date. This
option grant shall be subject to the terms and conditions of the Company's Stock
Option Plan and Stock Option Agreement. No right to any stock is earned or
accrued until such time that vesting occurs, nor does the grant confer any right
to continued vesting or employment.

     During each year of the employment term you may be entitled to a bonus of
up to $100,000 in cash or options on equity based on milestones to be set and
reviewed at the sole discretion of the CEO. The CEO and the Compensation
Committee of the Board of Directors will approve any payment of a bonus.

                    2401 4th Ave. Suite 1050 Seattle WA 98121
                             Main Phone 206.838.0500
                             Fax Number 206.838.0503

<PAGE>

     The Company is excited about your joining and looks forward to a beneficial
and productive relationship. Nevertheless, you should be aware that your
employment with the Company is for no specified period and constitutes at-will
employment. As a result, you are free to resign at any time, for any reason or
for no reason. Similarly, the Company is free to conclude its employment
relationship with you at any time, with or without cause, and with or without
notice. We request that, in the event of resignation, you give the Company at
least two weeks notice.

     The Company reserves the right to conduct background investigations and/or
reference checks on all of its potential employees. Your job offer, therefore,
is contingent upon a clearance of such a background investigation and/or
reference check, if any.

     For purposes of federal immigration law, you will be required to provide to
the Company documentary evidence of your identity and eligibility for employment
in the United States. Such documentation must be provided to us within three (3)
business days of your date of hire, or our employment relationship with you may
be terminated.

     We also ask that, if you have not already done so, you disclose to the
Company any and all agreements relating to your prior employment that may affect
your eligibility to be employed by the Company or limit the manner in which you
may be employed. It is the Company's understanding that any such agreements will
not prevent you from performing the duties of your position and you represent
that such is the case. Moreover, you agree that, during the term of your
employment with the Company, you will not engage in any other employment,
occupation, consulting or other business activity directly related to the
business in which the Company is now involved or becomes involved during the
term of your employment, nor will you engage in any other activities that
conflict with your obligations to the Company. Similarly, you agree not to bring
any third party confidential information to the Company, including that of your
former employer, and that in performing your duties for the Company you will not
in any way utilize any such information.

     As a Company employee, you will be expected to abide by the Company's rules
and standards. Specifically, you will be required to sign an acknowledgment that
you have read and that you understand the Company's rules of conduct which are
included in a handbook that the Company will deliver to you.

     As a condition of your employment, you are also required to sign and comply
with an Employment, Confidential Information, Invention Assignment,
Non-Competition and Arbitration Agreement (the "Agreement") which requires,
among other provisions, the assignment of patent rights to any invention made
during your employment at the Company, and non-disclosure of the Company's
proprietary information. In the event of any dispute or claim relating to or
arising out of our employment relationship, you and the Company agree that (i)
any and all disputes between you and the Company shall be fully and finally
resolved by binding arbitration, (ii) you are

                    2401 4th Ave. Suite 1050 Seattle WA 98121
                             Main Phone 206.838.0500
                             Fax Number 206.838.0503

<PAGE>

waiving any and all rights to a jury trial but all court remedies will be
available in arbitration, (iii) all disputes shall be resolved by a neutral
arbitrator who shall issue a written opinion, (iv) the arbitration shall provide
for adequate discovery, and (v) the Company and you shall each pay one-half of
the costs and expenses of such arbitration. Please note that we must receive
your signed Agreement before your first day of employment (please also initial
the Agreement where indicated).

     To accept the Company's offer, please sign and date this letter in the
space provided below. A duplicate original is enclosed for your records. This
letter, along with any agreements relating to proprietary rights between you and
the Company, set forth the terms of your employment with the Company and
supersede any prior representations or agreements including, but not limited to,
any representations made during your recruitment, interviews or pre-employment
negotiations, whether written or oral. This letter, including, but not limited
to, its at-will employment provision, may not be modified or amended except by a
written agreement signed by the President of the Company and you. This offer of
employment will terminate if it is not accepted, signed and returned by January
24, 2006.

     We look forward to your favorable reply and to working with you at Trubion
Pharmaceuticals, Inc.

                                         Sincerely,

                                         Trubion Pharmaceuticals, Inc.

                                         /s/ Peter Thompson
                                         ---------------------------------------
                                         Peter Thompson
                                         President and CEO

Agreed to and accepted:

Signature: /s/ Michelle Burris
           ---------------------------
Printed Name: Michelle Burris
Date: January 21, 2006

Enclosures: Duplicate Original Letter
            Employment, Confidential Information, Invention Assignment
            Non-Competition and Arbitration Agreement

                    2401 4th Ave. Suite 1050 Seattle WA 98121
                             Main Phone 206.838.0500
                             Fax Number 206.838.0503
<PAGE>

Stock Option Plan

                    2401 4th Ave. Suite 1050 Seattle WA 98121
                             Main Phone 206.838.0500
                             Fax Number 206.838.0503<PAGE>

                                                                   EXHIBIT 10.31

Dear Dr. Brettman:

     This letter describes me terms of your expanded advisory role with
GeneCraft, Inc. ("GeneCraft"). Please review the letter and, if the terms are
acceptable to you, sign it, and return a signed copy to me.

     As part of your expanded advisory role with GeneCraft, you agree to perform
the services described in the attached Exhibit A (the "Services"), for a period
commencing on January 1, 2003 and ending on January 1, 2007. Notwithstanding the
foregoing, either GeneCraft or you may terminate the advisory relationship
described herein prior to January 1, 2007 for any or no reason by giving the
other party thirty (30) days prior written notice. The confidentiality and
assignment obligations listed below will survive termination. As consideration
for your performance of the Services, GeneCraft will pay you the compensation
set forth in Exhibit A.

     You agree that your confidentiality obligations to GeneCraft arising in
connection with your service as a member of GeneCraft's Board of Directors apply
to your expanded advisory role with GeneCraft. Accordingly, you agree that you
will not disclose GeneCraft's confidential information or trade secrets or other
information GeneCraft is obligated to keep confidential to any third party or
use this information for any purpose other than in connection with the
performance of the Services and your obligations as a member of GeneCraft's
Board of Directors. You agree to take all reasonable precautions to prevent any
unauthorized disclosure of this information. In addition, you agree not to
disclose to GeneCraft any confidential information of any third party to whom
you owe non-disclosure obligations.

     As part of your expanded advisory role with GeneCraft, you may create works
of authorship and inventions for GeneCraft. Without a written commitment from
you, GeneCraft would not own these works and inventions. Therefore, you agree
that all works of authorship and inventions created by you specifically for
GeneCraft while performing the Services for GeneCraft will be the sole property
of GeneCraft. You hereby assign to GeneCraft all right, title, and interest in
and to these works and inventions, including all related intellectual property
rights. You also agree to assist GeneCraft to secure GeneCraft's rights in these
works and inventions and related intellectual property rights. You further agree
not to incorporate any pre-existing works or third party materials into the
works and inventions you create for GeneCraft while performing the Services
without the prior written consent of GeneCraft.

     Any term of this letter agreement and the attached Exhibit A may be amended
or waived only with the written consent of GeneCraft and you. This letter
agreement and the attached Exhibit A constitute the full and entire
understanding and agreement between GeneCraft and you with regard to the subject
hereof. This letter agreement shall be governed, construed and interpreted in
accordance with the laws of the State of Washington, without giving effect to
principles of conflicts of law. This letter agreement may be executed in two or
more counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.

                                        Sincerely,

                                        /s/ Peter A. Thompson
                                        ----------------------------------------
                                        Peter A. Thompson, MD, FACP
                                        President and CEO of GeneCraft

Acknowledged and agreed:

/s/ Lee R. Brettman
-------------------------------------
Lee. R. Bettman, MD, FACP

<PAGE>

                                    EXHIBIT A

                            SERVICES AND COMPENSATION

     1. Services. Services include the following:

     -    Providing input on clinical development planning for GeneCraft product
          candidates at and between meetings of GeneCraft's clinical development
          planning team;

     -    Providing input on implementation of GeneCraft's clinical development
          strategies;

     -    Providing input on research and development prioritization at and
          between meetings of GeneCraft's research and development strategic
          planning team; and

     -    Other activities as mutually agreed upon by you and GeneCraft.

     2. Compensation. GeneCraft will recommend at the first meeting of
GeneCraft's Board of Directors following the date of this letter that GeneCraft
grant you the right to purchase 100,000 shares of GeneCraft's Common Stock (the
"Shares") at a price per share equal to the fair market value per share of the
Common Stock on the date of purchase. The Shares will be sold pursuant to
GeneCraft's standard form of Restricted Stock Purchase Agreement and will be
subject to a right of repurchase on the part of GeneCraft that will lapse as
follows: GeneCraft's repurchase right will lapse as to 25% of the Shares upon
the date of purchase and, as to the remaining Shares, at the rate of 1/36th of
such Shares each month thereafter, subject to your continued provision of the
Services on the applicable dates.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]